A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...
Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...
Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate ...
BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...
A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...
The Brighterside of News on MSN
New drug combo cuts risk of death for men with prostate cancer by 40%
Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...
A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...
A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.
Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.
Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...
On-treatment PSA and disease burden should be considered together for prognostication. Achieving PSA ≤0.2 ng/mL within 6–12 weeks strongly predicts favorable long-term survival. Metastatic volume and ...
The Gleason score reliably predicts lethal prostate cancer for up to 25 years after diagnosis. High-grade prostate cancers progress rapidly in the short term, while lower grade tumors can still lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback